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ABSTRACT 
Background: Human herpesvirus- (HHV-6) infection is wide- 
spread throughout the world. No data are available in Argentina 
about the loss of maternally derived HHV-6 immunity and nat- 
ural infection in infants. 
Methods: A population of 100 pregnant women and 407 chil- 
dren between 1 and 1.5 months of age were assayed by indi- 
rect immunofluorescence to detect and quantify specific IgG 
anti-human herpesvirus- (anti-HHV-6) antibodies in C6rdoba 
City, Argentina. 
Results: There was no significant difference in the positive rate 
between infants aged 1 to 9 months (range, 43.6355%) and 
pregnant women (37%). Seropositive ratio dropped in the IO- 
month group (23.33% seropositive) and rose sharply in the II- 
month group (38.89%), 12-month (60.61%), and 13- to 
15.month group (63.46%). The geometric mean titer (GMT) for 
infants in the 12 to 15 months age group (23.4-41.64) was 
significantly higher than the GMT for infants IO months of age 
(11.04) (P < 0.05 with the Tukey-HSD test). 
Conclusions: This study shows a significant association 
between loss of passive HHV-6 antibody and age among 
infants. The results support evidence that HHV-6 enters the 
susceptible population at 11 months, leading to a high preva- 
lence of antibodies in children between 13 and 15 months of 
age. 
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In 1986, Salahuddin and colleagues reported the identi- 
fication of human herpesvirus- (HHV-6) and its isolation 
from patients with lymphoproliferative disorders, includ- 
ing acquired immunodeficiency syndrome (AIDS).’ The 
impact of HHV-6 on the human population is largely 
unknown, although HHV-6 is generally accepted as the 
primary cause of exanthem subitum, or roseola infantum, 
a mild childhood disease.’ There is a wide range of clin- 
ical findings associated with primary HHV-6 infection and 
reactivation3 In patients with human immunodeficiency 
virus (HIV) infection, HHV-6 has been proposed as a 
cofactor in the pathogenesis of AIDS.* Several viral strains 
have been isolated and subgrouped into two types, 
referred to as HHV-6 variant A (whose prototype is the 
inital isolate G.S.) and HHV-6 variant B (with character- 
istics similar to 229 prototypeX5 
A variety of strategies have been employed in the 
development of assays for detection of HHV-6 antibodies.’ 
Indirect immunofluorescence assay has previously been 
shown to be a sensitive and specific method adapted for 
the diagnosis of the HHV-6 infection.’ 
Recent studies support the ubiquity of HHV-6 in most 
populations, but racial-ethnic-geographic variation has 
been observed.8 Information regarding patterns of infec- 
tion outside the developed countries is limited. No data 
are available in Argentina about the duration of passive 
HHV-6 immunity or the age at which people are more 
susceptible to infection by HHV-6. The goal of this article 
is to provide evidence about the loss of maternally 
derived immunity and HHV-6 natural infection in Argen- 
tinian infants, identifying its particular characteristics. 
MATERIALS AND METHODS 
Population Study 
C6rdoba is the capital city of the Province of Cbrdoba, 
with a population of 2,750,OOO. Sera from 407 healthy 
infants (aged between 1 and 15 mo) and 100 pregnant 
women collected during routine checkups in 1995-96 
in the Children’s Hospital and in the General Direction 
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Table 1. Concentrahons of HHV-6Antibodies of Pregnant Women and Infants according to Age Group 
Seropositive* 
Age (mo complete) Number 
Pregnantwomen(n = 100) 37 
Infants 
l-3(n=39) 17 
4-6(n =70) 25 
7 (n = 28) 9 
8(n = 41) 14 
9 (n = 45) 16 
lO(n=30) 7 
11 (n = 36) 14 
12 (n = 66) 40 
13-15(n =52) 33 
Total (n = 507) 212 
*Antibodv titers 21 :I 0 were considered sbnificant. 
% (95% cl) 
37.0 (46.20-27.80) 
43.6 (58.00-29.20) 
35.7 (47.00-24.40) 
32.14 (49.14-15.14) 
34.15 (48.65-19.65) 
35.55 (49.55-21.55) 
23.33 (37.53-9.130) 
38.89 (53.99-23.79) 
60.61 (72.71-48.51) 
63.46 (76.46-50.46) 
40.44 (44.74-36.14) 
GMT of Seropositive Children (Antibody Range) 
15.68(18.09-13.27) 
17.70(19.63-15.77) 
17.9 (21.26-14.54) 
11.66 (13.79-9.530) 
12.21 (13.59-10.83) 
16.10 (18.48-13.72) 
11.04(13.57-8.510) 
15.62 (17.84-13.40) 
23.40 (26.20-20.60) 
41.64 (45.86-37.42) 
19.41 (22.32-16.50) 
GMT = gkometric mean titers. 
of Medical Specialities in C6rdoba City were used to inves- 
tigate the duration of transplacentally derived HHV-6 anti- 
body. Written consent was obtained from the parents of 
the children. Thirty-nine percent of the women were in 
the first trimester of pregnancy, 43% in the second 
trimester, and 18% in the third trimester. Fit@-five percent 
of the pregnant women ranged between 20 and 29 years 
of age (range, 15-42 y). All infants were born after 36 
weeks of gestation, weighing >2500 g. The female-to-male 
ratio was 1.0:1.3. 
Serologic Evaluation 
An indirect imrnunofluorescence assay (IFA) was performed 
using multiwell Tefloncoated slides prepared with the lym- 
phoid cell line MOLT-3, infected with the 229 HHV-6 viral 
strain. Previously, it was determined that the optimal postin- 
fection culture day to be used as a source of viral antigen 
was day 16 postinfection (data not shown). Staining for IFA 
was performed by the standard procedure used in the lab- 
oratory. Briefly, lo-fold dilutions of serum samples were 
incubated with fixed cells for 30 minutes at 37°C in a 
humidified chamber, washed twice by phosphate buffered 
saline (PBS) for 5 minutes and incubated for 30 minutes 
at 37°C with fluorescein isothiocyanate-conjugated goat 
antihuman IgG serum. The slides were mounted with glyc- 
erol buffer on coverslips and then examined under a flu- 
orescent microscope. The highest serum dilution that 
exhibited a specific fluorescense pattern was considered 
the endpoint of antibody titration. Titers of 1: I 0 or higher 
were considered significant. 
Data Analysis 
Geometric mean titers (GMT) were calculated only for 
individuals with detectable antibodies in the following 
way: the reciprocals of HHV-6 antibody titers were loga- 
rithmically converted and the antilogarithm was calcu- 
lated. A comparison of the mean value obtained with the 
Tukey high significant difference @SD) test with a 95% 
level of confidence was made. 
RESULTS 
Results for the pregnant women and maternally derived 
HHVG antibody titers by age groups are summarized in 
Table 1. There was no significant difference in the posi- 
tive rate between infants ages 1 to 9 months (range, 
43.6-35.5%) and pregnant women (37%). Seropositive 
ratio dropped in the IO-month group (23.33% seroposi- 
tive) and rose sharply in the 11-month group (38.89%), 
12-month (60.61%), and 13- to 15-month group (63.46%) 
(Figure 1). 
The exact antibody titers were measured in both the 
pregnant women and the infant seropositive individuals. 
The GMT for infants 12 to 15 months of age (23.4-41.64) 
was significantly higher than the HHV-6 GMT for lo- 
month-old infants (11.04) (P < 0.05>, with the Tukey-HSD 
test. No significant difference in the antibody titers or in 
the rate of immunity was found between female and male 
children in the age groups nor among the different preg- 
nancy terms studied. 
DISCUSSION 
Human herpesvirus- infection is widespread through- 
out the world. Among various populations, the rates of 
HHV-6 seroprevalence have been reported to be as low 
as 20% among pregnant Moroccan women and as high 
as 100% among Chinese adults.9 In the present study, the 
prevalence of antibody found in pregnant women (37%) 
was similar to the results reported byYadav et al in North 
Borneo.‘” At the same time, it contrasts with the preva- 
lence found in neighboring African countries (Sahara, 
60-90%), in Ecuador (92%), and in France (76%).9 These 
differences could be explained by various regional factors 
(ethnic, genetic, socioeconomic, etc.), as proposed by 
Levine et al,* that would contribute to or facilitate the 
reactivation of the infection in adults. 
Seroprevalence of antibodies in pregnant women 
indirectly reflects HHV-6 circulation in their infants in 
early life. In the present study, low maternal antibody 
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Figure 1. Prevalence of HHV-6 antibodies and the geometric mean 
titers of HHV-6 detectable antibodies by age group. 
prevalence was observed among a group of infants highly 
exposed to primary infection since early age. 
The statistical significance found in the prevalence 
and the GMT between the group 12 to 15 months of 
age and the lo-month group, indicates that the mater- 
nal antibodies progressively decrease until 9 to 10 
months of age. The prevalence and GMT of the infants 
exhibits similar declines (see Figure 1). Significant 
increase in antibody prevalence and GMT among 
infants over 11 months of age would point at the onset 
of primary infection among the infant population. Sim- 
ilar data were reported by Roldan and colleagues, from 
Spain.” Although there has been no direct proof of 
protection by maternal HHV-6 antibodies, several stud- 
ies,‘2x*3 including this one, have found that HHV-6 infec- 
tion increases after the first months of life, intimating 
a protective role for the maternal antibody. If so, the 
prevalence and antibody titers observed in the lo- 
month-old infants would be as a result of the addition 
of antibodies provided by the children that preserve 
the maternal immunity at low levels and others that 
have been primoinfected. 
The high chance of infection noted between 12 and 
15 months of age may be related to the frequent oral 
exploration of the environment by children of this age 
group that allows contact with saliva or saliva-contami- 
nated fomites.‘* This study also reveals a significant dif- 
ference in seroprevalence between adults (i.e., pregnant 
women, 37%) and I5-month-old children (63.46%). Stud- 
ies of the age-related prevalence of antibody revealed a 
decrease in seroprevalence and titer with age,15 suggest- 
ing that reinfection or reactivation of HHV6 may not fre- 
quently occur after initial infection. 
The limited knowledge about the behavior of HHV-6 
in healthy subjects makes the study of the prevalence of 
circulating antibody relevant to the study and analysis of 
the effects of emerging viruses in infant populations. 
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